In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Duker about a sustained-release tyrosine kinase inhibitor that could redefine the durability and convenience of anti-VEGF therapy.
Jay S. Duker, MD
Advertisement
Articles by Jay S. Duker, MD
Study aims to identify methodology for least amount of variation, greatest test-retest reliability
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Modern Retina
1
Retina World Congress 2026: Identifying real-world durability gaps in wet AMD treatment
2
Retina World Congress 2026: Rethinking macular hole surgery without gas tamponade
3
Retina World Congress 2026: Can vibration reduce pain during intravitreal injections?
4
Retina World Congress 2026: Diagnosing macular telangiectasia in a field of mimickers
5